Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 09/16/15 → 09/15/25 |
Funding
- Merck Sharp and Dohme Limited Liability Corporation: $168,869.66
A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Sivapiragasam, Abirami (PI)
- Gajra, Ajeet (PI)
Project: Research